Skip to content
CompletedPhase 1

PsilOCD: A Pharmacological-Challenge Feasibility Study

NCT06258031 · Imperial College London

Closed to entry
Status
Not accepting participants
Phase 1
Phase
19
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The purpose of this study is to assess the impact of psilocybin on cognitive inflexibility and neural plasticity in a cohort of people with obsessive-compulsive disorder (OCD).

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Intradimensional-extradimensional (ID-ED) set shift

    Measured over 4 weeks

  • The visual long-term potentiation (vLTP) electroencephalogram (EEG) paradigm (acute quantified changes in neuroplasticity in the visual system).

    Measured over 8 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

20 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Key Inclusion Criteria: * Aged 20 to 65 years; * Any gender; * A primary diagnosis of OCD (based on the Mini-International Neuropsychiatric Interview (M.I.N.I.)); * Has met diagnostic criteria for OCD for at least 12 months; * Willing to comply with protocol and associated lifestyle restrictions; * Adequate understanding of the English language to give informed consent and participate in the study; * Participant can attend visits as an outpatient; * Comfortable using a computer, access to internet from home, and willing to participate in some of the study visits via video-link. Key Exclusion Criteria: * Current or past history of dependent (according to ICD10 criteria) substance use (not including nicotine and/or caffeine), Tourette's syndrome, autism spectrum disorder, epilepsy, organic mental disorder, or a personality disorder apart from obsessive-compulsive personality disorder; * Current or past history of psychosis or mania in themselves or a first-degree relative; * Unstable physical health; * Significantly abnormal clinical test result; * Heavy smoker, or unable to attend the dosing days (including the subsequent recovery part) without a smoking break; * Unwillingness to allow their GP or mental health practitioners to be informed of their participation (or, to allow study team access to Summary Care Record).

Where

1 study site

FacilityCityRegionCountry
CIPPRes ClinicLondonUnited Kingdom

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06258031 on ClinicalTrials.gov →

Last updated in the registry 2024-11-06. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits